| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Scientific Officer | Chief Scientific Officer
1 company
Edward P. Feener last filed a Form 4 in May 2024, as Chief Scientific Officer at KALV. Edward P. Feener's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Edward P. Feener's trades have earned a strong insider score of 72/100 across 17 rated trades. Over a 12-month horizon, 64.7% of those trades were profitable, with an average 12-month return of +18.0%.
At the last filing, the largest reported position was 72,858 shares of KALV. The KALV filings lean toward selling, a net 237,857 shares.
Edward P. Feener has 34 Form 4 filings on record from November 2016 to May 2024, all as Chief Scientific Officer at KalVista Pharmaceuticals (KALV), 2016–2024.
The 66 reported transactions were 38 open-market sales, 13 option or other derivative awards, 11 option exercises and 3 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 23 sales worth about $4.6M.
The largest open-market sale was 31,000 shares of KALV at an average $33.60 on February 23, 2021, about $1.0M.
4 of the 8 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 4 were not.
Shares as reported in the last Form 4 for each company; the most recent is from May 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 20, 2024 | KALV Kalvista Pharmaceuticals, Inc. | Chief Scientific Officer | Sale+OE10b5-1 | 8,088 | $11.76 | $95,151.28 | -10.0% | +3.0% | +3.0% | |
| Feb 20, 2024 | KALV Kalvista Pharmaceuticals, Inc. | Chief Scientific Officer | Sale+OE10b5-1 | 28,288 | $14.07 | $397,929.01 | -31.3% | -13.9% | -22.4% | |
| Feb 14, 2024 | KALV Kalvista Pharmaceuticals, Inc. | Chief Scientific Officer | Sell | 28,171 | $15.01 | $422,826.99 | -28.2% | -13.3% | -33.8% | |
| Jan 11, 2024 | KALV Kalvista Pharmaceuticals, Inc. | Chief Scientific Officer | Sell10b5-1 | 22,679 | $13.03 | $295,514.17 | -36.3% | -9.1% | -40.2% | |
| Jan 9, 2024 | KALV Kalvista Pharmaceuticals, Inc. | Chief Scientific Officer | Sell10b5-1 | 17,321 | $13.01 | $225,300.44 | -21.7% | -13.5% | -35.5% | |
| Nov 20, 2023 | KALV Kalvista Pharmaceuticals, Inc. | Chief Scientific Officer | Sale+OE | 4,958 | $8.23 | $40,800.87 | -5.8% | +68.1% | +10.2% | |
| Aug 18, 2023 | KALV Kalvista Pharmaceuticals, Inc. | Chief Scientific Officer | Sale+OE | 4,976 | $10.73 | $53,386.01 | -6.4% | -29.4% | +11.3% | |
| May 18, 2023 | KALV Kalvista Pharmaceuticals, Inc. | Chief Scientific Officer | Sale+OE | 1,786 | $10.14 | $18,117.90 | -2.6% | +3.7% | +14.6% | |
| Feb 17, 2023 | KALV Kalvista Pharmaceuticals, Inc. | Chief Scientific Officer | Sale+OE | 2,228 | $7.66 | $17,066.48 | -3.3% | +28.1% | +83.0% | |
| Nov 18, 2022 | KALV Kalvista Pharmaceuticals, Inc. | Chief Scientific Officer | Sale+OE | 530 | $5.44 | $2,883.20 | -0.8% | +49.7% | +59.5% |